Global Gene Engineered Subunit Vaccine Market 2023 by Company, Regions, Type and Application, Forecast to 2029
A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.
According to our (Global Info Research) latest study, the global Gene Engineered Subunit Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Gene Engineered Subunit Vaccine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Gene Engineered Subunit Vaccine market size and forecasts, in consumption value ($ Million), 2018-2029
Global Gene Engineered Subunit Vaccine market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Gene Engineered Subunit Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Gene Engineered Subunit Vaccine market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Engineered Subunit Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene Engineered Subunit Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, GSK, Tiantan, Pulike and Greffex, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Gene Engineered Subunit Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Gene Engineered Subunit Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Engineered Subunit Vaccine, with revenue, gross margin and global market share of Gene Engineered Subunit Vaccine from 2018 to 2023.
Chapter 3, the Gene Engineered Subunit Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Engineered Subunit Vaccine market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Engineered Subunit Vaccine.
Chapter 13, to describe Gene Engineered Subunit Vaccine research findings and conclusion.
According to our (Global Info Research) latest study, the global Gene Engineered Subunit Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Gene Engineered Subunit Vaccine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Gene Engineered Subunit Vaccine market size and forecasts, in consumption value ($ Million), 2018-2029
Global Gene Engineered Subunit Vaccine market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Gene Engineered Subunit Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Gene Engineered Subunit Vaccine market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Engineered Subunit Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene Engineered Subunit Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, GSK, Tiantan, Pulike and Greffex, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Gene Engineered Subunit Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Therapeutic Gene Engineered Subunit Vaccine
- Preventative Gene Engineered Subunit Vaccine
- Human Use
- Veterinary Use
- Merck
- GSK
- Tiantan
- Pulike
- Greffex
- CureVac
- Yebio
- Sanofi Pasteur SA
- Virbac
- Pfizer Inc.
- Walvax Biotechnology
- Kontec
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Gene Engineered Subunit Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Engineered Subunit Vaccine, with revenue, gross margin and global market share of Gene Engineered Subunit Vaccine from 2018 to 2023.
Chapter 3, the Gene Engineered Subunit Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Engineered Subunit Vaccine market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Engineered Subunit Vaccine.
Chapter 13, to describe Gene Engineered Subunit Vaccine research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Gene Engineered Subunit Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gene Engineered Subunit Vaccine by Type
1.3.1 Overview: Global Gene Engineered Subunit Vaccine Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Type in 2022
1.3.3 Therapeutic Gene Engineered Subunit Vaccine
1.3.4 Preventative Gene Engineered Subunit Vaccine
1.4 Global Gene Engineered Subunit Vaccine Market by Application
1.4.1 Overview: Global Gene Engineered Subunit Vaccine Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Human Use
1.4.3 Veterinary Use
1.5 Global Gene Engineered Subunit Vaccine Market Size & Forecast
1.6 Global Gene Engineered Subunit Vaccine Market Size and Forecast by Region
1.6.1 Global Gene Engineered Subunit Vaccine Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Gene Engineered Subunit Vaccine Market Size by Region, (2018-2029)
1.6.3 North America Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.4 Europe Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.6 South America Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Gene Engineered Subunit Vaccine Product and Solutions
2.1.4 Merck Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Merck Recent Developments and Future Plans
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Gene Engineered Subunit Vaccine Product and Solutions
2.2.4 GSK Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 GSK Recent Developments and Future Plans
2.3 Tiantan
2.3.1 Tiantan Details
2.3.2 Tiantan Major Business
2.3.3 Tiantan Gene Engineered Subunit Vaccine Product and Solutions
2.3.4 Tiantan Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Tiantan Recent Developments and Future Plans
2.4 Pulike
2.4.1 Pulike Details
2.4.2 Pulike Major Business
2.4.3 Pulike Gene Engineered Subunit Vaccine Product and Solutions
2.4.4 Pulike Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Pulike Recent Developments and Future Plans
2.5 Greffex
2.5.1 Greffex Details
2.5.2 Greffex Major Business
2.5.3 Greffex Gene Engineered Subunit Vaccine Product and Solutions
2.5.4 Greffex Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Greffex Recent Developments and Future Plans
2.6 CureVac
2.6.1 CureVac Details
2.6.2 CureVac Major Business
2.6.3 CureVac Gene Engineered Subunit Vaccine Product and Solutions
2.6.4 CureVac Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 CureVac Recent Developments and Future Plans
2.7 Yebio
2.7.1 Yebio Details
2.7.2 Yebio Major Business
2.7.3 Yebio Gene Engineered Subunit Vaccine Product and Solutions
2.7.4 Yebio Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Yebio Recent Developments and Future Plans
2.8 Sanofi Pasteur SA
2.8.1 Sanofi Pasteur SA Details
2.8.2 Sanofi Pasteur SA Major Business
2.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product and Solutions
2.8.4 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Sanofi Pasteur SA Recent Developments and Future Plans
2.9 Virbac
2.9.1 Virbac Details
2.9.2 Virbac Major Business
2.9.3 Virbac Gene Engineered Subunit Vaccine Product and Solutions
2.9.4 Virbac Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Virbac Recent Developments and Future Plans
2.10 Pfizer Inc.
2.10.1 Pfizer Inc. Details
2.10.2 Pfizer Inc. Major Business
2.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Product and Solutions
2.10.4 Pfizer Inc. Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer Inc. Recent Developments and Future Plans
2.11 Walvax Biotechnology
2.11.1 Walvax Biotechnology Details
2.11.2 Walvax Biotechnology Major Business
2.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Product and Solutions
2.11.4 Walvax Biotechnology Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Walvax Biotechnology Recent Developments and Future Plans
2.12 Kontec
2.12.1 Kontec Details
2.12.2 Kontec Major Business
2.12.3 Kontec Gene Engineered Subunit Vaccine Product and Solutions
2.12.4 Kontec Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Kontec Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Gene Engineered Subunit Vaccine Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Gene Engineered Subunit Vaccine by Company Revenue
3.2.2 Top 3 Gene Engineered Subunit Vaccine Players Market Share in 2022
3.2.3 Top 6 Gene Engineered Subunit Vaccine Players Market Share in 2022
3.3 Gene Engineered Subunit Vaccine Market: Overall Company Footprint Analysis
3.3.1 Gene Engineered Subunit Vaccine Market: Region Footprint
3.3.2 Gene Engineered Subunit Vaccine Market: Company Product Type Footprint
3.3.3 Gene Engineered Subunit Vaccine Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Gene Engineered Subunit Vaccine Consumption Value and Market Share by Type (2018-2023)
4.2 Global Gene Engineered Subunit Vaccine Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2023)
5.2 Global Gene Engineered Subunit Vaccine Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
6.2 North America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
6.3 North America Gene Engineered Subunit Vaccine Market Size by Country
6.3.1 North America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
6.3.2 United States Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
6.3.3 Canada Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
6.3.4 Mexico Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
7.2 Europe Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
7.3 Europe Gene Engineered Subunit Vaccine Market Size by Country
7.3.1 Europe Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
7.3.2 Germany Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.3 France Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.5 Russia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.6 Italy Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region
8.3.1 Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Region (2018-2029)
8.3.2 China Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.3 Japan Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.4 South Korea Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.5 India Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.7 Australia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
9.2 South America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
9.3 South America Gene Engineered Subunit Vaccine Market Size by Country
9.3.1 South America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
9.3.2 Brazil Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
9.3.3 Argentina Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country
10.3.1 Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
10.3.2 Turkey Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
10.3.4 UAE Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Gene Engineered Subunit Vaccine Market Drivers
11.2 Gene Engineered Subunit Vaccine Market Restraints
11.3 Gene Engineered Subunit Vaccine Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Gene Engineered Subunit Vaccine Industry Chain
12.2 Gene Engineered Subunit Vaccine Upstream Analysis
12.3 Gene Engineered Subunit Vaccine Midstream Analysis
12.4 Gene Engineered Subunit Vaccine Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Gene Engineered Subunit Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gene Engineered Subunit Vaccine by Type
1.3.1 Overview: Global Gene Engineered Subunit Vaccine Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Type in 2022
1.3.3 Therapeutic Gene Engineered Subunit Vaccine
1.3.4 Preventative Gene Engineered Subunit Vaccine
1.4 Global Gene Engineered Subunit Vaccine Market by Application
1.4.1 Overview: Global Gene Engineered Subunit Vaccine Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Human Use
1.4.3 Veterinary Use
1.5 Global Gene Engineered Subunit Vaccine Market Size & Forecast
1.6 Global Gene Engineered Subunit Vaccine Market Size and Forecast by Region
1.6.1 Global Gene Engineered Subunit Vaccine Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Gene Engineered Subunit Vaccine Market Size by Region, (2018-2029)
1.6.3 North America Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.4 Europe Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.6 South America Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Gene Engineered Subunit Vaccine Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Gene Engineered Subunit Vaccine Product and Solutions
2.1.4 Merck Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Merck Recent Developments and Future Plans
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Gene Engineered Subunit Vaccine Product and Solutions
2.2.4 GSK Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 GSK Recent Developments and Future Plans
2.3 Tiantan
2.3.1 Tiantan Details
2.3.2 Tiantan Major Business
2.3.3 Tiantan Gene Engineered Subunit Vaccine Product and Solutions
2.3.4 Tiantan Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Tiantan Recent Developments and Future Plans
2.4 Pulike
2.4.1 Pulike Details
2.4.2 Pulike Major Business
2.4.3 Pulike Gene Engineered Subunit Vaccine Product and Solutions
2.4.4 Pulike Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Pulike Recent Developments and Future Plans
2.5 Greffex
2.5.1 Greffex Details
2.5.2 Greffex Major Business
2.5.3 Greffex Gene Engineered Subunit Vaccine Product and Solutions
2.5.4 Greffex Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Greffex Recent Developments and Future Plans
2.6 CureVac
2.6.1 CureVac Details
2.6.2 CureVac Major Business
2.6.3 CureVac Gene Engineered Subunit Vaccine Product and Solutions
2.6.4 CureVac Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 CureVac Recent Developments and Future Plans
2.7 Yebio
2.7.1 Yebio Details
2.7.2 Yebio Major Business
2.7.3 Yebio Gene Engineered Subunit Vaccine Product and Solutions
2.7.4 Yebio Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Yebio Recent Developments and Future Plans
2.8 Sanofi Pasteur SA
2.8.1 Sanofi Pasteur SA Details
2.8.2 Sanofi Pasteur SA Major Business
2.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product and Solutions
2.8.4 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Sanofi Pasteur SA Recent Developments and Future Plans
2.9 Virbac
2.9.1 Virbac Details
2.9.2 Virbac Major Business
2.9.3 Virbac Gene Engineered Subunit Vaccine Product and Solutions
2.9.4 Virbac Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Virbac Recent Developments and Future Plans
2.10 Pfizer Inc.
2.10.1 Pfizer Inc. Details
2.10.2 Pfizer Inc. Major Business
2.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Product and Solutions
2.10.4 Pfizer Inc. Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer Inc. Recent Developments and Future Plans
2.11 Walvax Biotechnology
2.11.1 Walvax Biotechnology Details
2.11.2 Walvax Biotechnology Major Business
2.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Product and Solutions
2.11.4 Walvax Biotechnology Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Walvax Biotechnology Recent Developments and Future Plans
2.12 Kontec
2.12.1 Kontec Details
2.12.2 Kontec Major Business
2.12.3 Kontec Gene Engineered Subunit Vaccine Product and Solutions
2.12.4 Kontec Gene Engineered Subunit Vaccine Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Kontec Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Gene Engineered Subunit Vaccine Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Gene Engineered Subunit Vaccine by Company Revenue
3.2.2 Top 3 Gene Engineered Subunit Vaccine Players Market Share in 2022
3.2.3 Top 6 Gene Engineered Subunit Vaccine Players Market Share in 2022
3.3 Gene Engineered Subunit Vaccine Market: Overall Company Footprint Analysis
3.3.1 Gene Engineered Subunit Vaccine Market: Region Footprint
3.3.2 Gene Engineered Subunit Vaccine Market: Company Product Type Footprint
3.3.3 Gene Engineered Subunit Vaccine Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Gene Engineered Subunit Vaccine Consumption Value and Market Share by Type (2018-2023)
4.2 Global Gene Engineered Subunit Vaccine Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2023)
5.2 Global Gene Engineered Subunit Vaccine Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
6.2 North America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
6.3 North America Gene Engineered Subunit Vaccine Market Size by Country
6.3.1 North America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
6.3.2 United States Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
6.3.3 Canada Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
6.3.4 Mexico Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
7.2 Europe Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
7.3 Europe Gene Engineered Subunit Vaccine Market Size by Country
7.3.1 Europe Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
7.3.2 Germany Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.3 France Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.5 Russia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
7.3.6 Italy Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region
8.3.1 Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Region (2018-2029)
8.3.2 China Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.3 Japan Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.4 South Korea Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.5 India Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
8.3.7 Australia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
9.2 South America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
9.3 South America Gene Engineered Subunit Vaccine Market Size by Country
9.3.1 South America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
9.3.2 Brazil Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
9.3.3 Argentina Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country
10.3.1 Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2029)
10.3.2 Turkey Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
10.3.4 UAE Gene Engineered Subunit Vaccine Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Gene Engineered Subunit Vaccine Market Drivers
11.2 Gene Engineered Subunit Vaccine Market Restraints
11.3 Gene Engineered Subunit Vaccine Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Gene Engineered Subunit Vaccine Industry Chain
12.2 Gene Engineered Subunit Vaccine Upstream Analysis
12.3 Gene Engineered Subunit Vaccine Midstream Analysis
12.4 Gene Engineered Subunit Vaccine Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Gene Engineered Subunit Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gene Engineered Subunit Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Gene Engineered Subunit Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Gene Engineered Subunit Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Merck Company Information, Head Office, and Major Competitors
Table 6. Merck Major Business
Table 7. Merck Gene Engineered Subunit Vaccine Product and Solutions
Table 8. Merck Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Merck Recent Developments and Future Plans
Table 10. GSK Company Information, Head Office, and Major Competitors
Table 11. GSK Major Business
Table 12. GSK Gene Engineered Subunit Vaccine Product and Solutions
Table 13. GSK Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. GSK Recent Developments and Future Plans
Table 15. Tiantan Company Information, Head Office, and Major Competitors
Table 16. Tiantan Major Business
Table 17. Tiantan Gene Engineered Subunit Vaccine Product and Solutions
Table 18. Tiantan Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Tiantan Recent Developments and Future Plans
Table 20. Pulike Company Information, Head Office, and Major Competitors
Table 21. Pulike Major Business
Table 22. Pulike Gene Engineered Subunit Vaccine Product and Solutions
Table 23. Pulike Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Pulike Recent Developments and Future Plans
Table 25. Greffex Company Information, Head Office, and Major Competitors
Table 26. Greffex Major Business
Table 27. Greffex Gene Engineered Subunit Vaccine Product and Solutions
Table 28. Greffex Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Greffex Recent Developments and Future Plans
Table 30. CureVac Company Information, Head Office, and Major Competitors
Table 31. CureVac Major Business
Table 32. CureVac Gene Engineered Subunit Vaccine Product and Solutions
Table 33. CureVac Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. CureVac Recent Developments and Future Plans
Table 35. Yebio Company Information, Head Office, and Major Competitors
Table 36. Yebio Major Business
Table 37. Yebio Gene Engineered Subunit Vaccine Product and Solutions
Table 38. Yebio Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Yebio Recent Developments and Future Plans
Table 40. Sanofi Pasteur SA Company Information, Head Office, and Major Competitors
Table 41. Sanofi Pasteur SA Major Business
Table 42. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product and Solutions
Table 43. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Sanofi Pasteur SA Recent Developments and Future Plans
Table 45. Virbac Company Information, Head Office, and Major Competitors
Table 46. Virbac Major Business
Table 47. Virbac Gene Engineered Subunit Vaccine Product and Solutions
Table 48. Virbac Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Virbac Recent Developments and Future Plans
Table 50. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 51. Pfizer Inc. Major Business
Table 52. Pfizer Inc. Gene Engineered Subunit Vaccine Product and Solutions
Table 53. Pfizer Inc. Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Pfizer Inc. Recent Developments and Future Plans
Table 55. Walvax Biotechnology Company Information, Head Office, and Major Competitors
Table 56. Walvax Biotechnology Major Business
Table 57. Walvax Biotechnology Gene Engineered Subunit Vaccine Product and Solutions
Table 58. Walvax Biotechnology Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Walvax Biotechnology Recent Developments and Future Plans
Table 60. Kontec Company Information, Head Office, and Major Competitors
Table 61. Kontec Major Business
Table 62. Kontec Gene Engineered Subunit Vaccine Product and Solutions
Table 63. Kontec Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Kontec Recent Developments and Future Plans
Table 65. Global Gene Engineered Subunit Vaccine Revenue (USD Million) by Players (2018-2023)
Table 66. Global Gene Engineered Subunit Vaccine Revenue Share by Players (2018-2023)
Table 67. Breakdown of Gene Engineered Subunit Vaccine by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Gene Engineered Subunit Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Gene Engineered Subunit Vaccine Players
Table 70. Gene Engineered Subunit Vaccine Market: Company Product Type Footprint
Table 71. Gene Engineered Subunit Vaccine Market: Company Product Application Footprint
Table 72. Gene Engineered Subunit Vaccine New Market Entrants and Barriers to Market Entry
Table 73. Gene Engineered Subunit Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Gene Engineered Subunit Vaccine Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Gene Engineered Subunit Vaccine Consumption Value Share by Type (2018-2023)
Table 76. Global Gene Engineered Subunit Vaccine Consumption Value Forecast by Type (2024-2029)
Table 77. Global Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023)
Table 78. Global Gene Engineered Subunit Vaccine Consumption Value Forecast by Application (2024-2029)
Table 79. North America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Gene Engineered Subunit Vaccine Raw Material
Table 110. Key Suppliers of Gene Engineered Subunit Vaccine Raw Materials
Table 1. Global Gene Engineered Subunit Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gene Engineered Subunit Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Gene Engineered Subunit Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Gene Engineered Subunit Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Merck Company Information, Head Office, and Major Competitors
Table 6. Merck Major Business
Table 7. Merck Gene Engineered Subunit Vaccine Product and Solutions
Table 8. Merck Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Merck Recent Developments and Future Plans
Table 10. GSK Company Information, Head Office, and Major Competitors
Table 11. GSK Major Business
Table 12. GSK Gene Engineered Subunit Vaccine Product and Solutions
Table 13. GSK Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. GSK Recent Developments and Future Plans
Table 15. Tiantan Company Information, Head Office, and Major Competitors
Table 16. Tiantan Major Business
Table 17. Tiantan Gene Engineered Subunit Vaccine Product and Solutions
Table 18. Tiantan Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Tiantan Recent Developments and Future Plans
Table 20. Pulike Company Information, Head Office, and Major Competitors
Table 21. Pulike Major Business
Table 22. Pulike Gene Engineered Subunit Vaccine Product and Solutions
Table 23. Pulike Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Pulike Recent Developments and Future Plans
Table 25. Greffex Company Information, Head Office, and Major Competitors
Table 26. Greffex Major Business
Table 27. Greffex Gene Engineered Subunit Vaccine Product and Solutions
Table 28. Greffex Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Greffex Recent Developments and Future Plans
Table 30. CureVac Company Information, Head Office, and Major Competitors
Table 31. CureVac Major Business
Table 32. CureVac Gene Engineered Subunit Vaccine Product and Solutions
Table 33. CureVac Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. CureVac Recent Developments and Future Plans
Table 35. Yebio Company Information, Head Office, and Major Competitors
Table 36. Yebio Major Business
Table 37. Yebio Gene Engineered Subunit Vaccine Product and Solutions
Table 38. Yebio Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Yebio Recent Developments and Future Plans
Table 40. Sanofi Pasteur SA Company Information, Head Office, and Major Competitors
Table 41. Sanofi Pasteur SA Major Business
Table 42. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product and Solutions
Table 43. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Sanofi Pasteur SA Recent Developments and Future Plans
Table 45. Virbac Company Information, Head Office, and Major Competitors
Table 46. Virbac Major Business
Table 47. Virbac Gene Engineered Subunit Vaccine Product and Solutions
Table 48. Virbac Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Virbac Recent Developments and Future Plans
Table 50. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 51. Pfizer Inc. Major Business
Table 52. Pfizer Inc. Gene Engineered Subunit Vaccine Product and Solutions
Table 53. Pfizer Inc. Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Pfizer Inc. Recent Developments and Future Plans
Table 55. Walvax Biotechnology Company Information, Head Office, and Major Competitors
Table 56. Walvax Biotechnology Major Business
Table 57. Walvax Biotechnology Gene Engineered Subunit Vaccine Product and Solutions
Table 58. Walvax Biotechnology Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Walvax Biotechnology Recent Developments and Future Plans
Table 60. Kontec Company Information, Head Office, and Major Competitors
Table 61. Kontec Major Business
Table 62. Kontec Gene Engineered Subunit Vaccine Product and Solutions
Table 63. Kontec Gene Engineered Subunit Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Kontec Recent Developments and Future Plans
Table 65. Global Gene Engineered Subunit Vaccine Revenue (USD Million) by Players (2018-2023)
Table 66. Global Gene Engineered Subunit Vaccine Revenue Share by Players (2018-2023)
Table 67. Breakdown of Gene Engineered Subunit Vaccine by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Gene Engineered Subunit Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 69. Head Office of Key Gene Engineered Subunit Vaccine Players
Table 70. Gene Engineered Subunit Vaccine Market: Company Product Type Footprint
Table 71. Gene Engineered Subunit Vaccine Market: Company Product Application Footprint
Table 72. Gene Engineered Subunit Vaccine New Market Entrants and Barriers to Market Entry
Table 73. Gene Engineered Subunit Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Gene Engineered Subunit Vaccine Consumption Value (USD Million) by Type (2018-2023)
Table 75. Global Gene Engineered Subunit Vaccine Consumption Value Share by Type (2018-2023)
Table 76. Global Gene Engineered Subunit Vaccine Consumption Value Forecast by Type (2024-2029)
Table 77. Global Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023)
Table 78. Global Gene Engineered Subunit Vaccine Consumption Value Forecast by Application (2024-2029)
Table 79. North America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 80. North America Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 81. North America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 82. North America Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 83. North America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 84. North America Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 85. Europe Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Europe Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Europe Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 88. Europe Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 89. Europe Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 92. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 93. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 94. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 95. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 96. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 97. South America Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 98. South America Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 99. South America Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 100. South America Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 101. South America Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 102. South America Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 104. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 105. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 106. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 107. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 108. Middle East & Africa Gene Engineered Subunit Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 109. Gene Engineered Subunit Vaccine Raw Material
Table 110. Key Suppliers of Gene Engineered Subunit Vaccine Raw Materials
LIST OF FIGURES
Figure 1. Gene Engineered Subunit Vaccine Picture
Figure 2. Global Gene Engineered Subunit Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Therapeutic Gene Engineered Subunit Vaccine
Figure 5. Preventative Gene Engineered Subunit Vaccine
Figure 6. Global Gene Engineered Subunit Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Gene Engineered Subunit Vaccine Consumption Value Market Share by Application in 2022
Figure 8. Human Use Picture
Figure 9. Veterinary Use Picture
Figure 10. Global Gene Engineered Subunit Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Gene Engineered Subunit Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Gene Engineered Subunit Vaccine Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Region in 2022
Figure 15. North America Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Gene Engineered Subunit Vaccine Revenue Share by Players in 2022
Figure 21. Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Gene Engineered Subunit Vaccine Market Share in 2022
Figure 23. Global Top 6 Players Gene Engineered Subunit Vaccine Market Share in 2022
Figure 24. Global Gene Engineered Subunit Vaccine Consumption Value Share by Type (2018-2023)
Figure 25. Global Gene Engineered Subunit Vaccine Market Share Forecast by Type (2024-2029)
Figure 26. Global Gene Engineered Subunit Vaccine Consumption Value Share by Application (2018-2023)
Figure 27. Global Gene Engineered Subunit Vaccine Market Share Forecast by Application (2024-2029)
Figure 28. North America Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 38. France Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 45. China Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 48. India Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 62. Gene Engineered Subunit Vaccine Market Drivers
Figure 63. Gene Engineered Subunit Vaccine Market Restraints
Figure 64. Gene Engineered Subunit Vaccine Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Gene Engineered Subunit Vaccine in 2022
Figure 67. Manufacturing Process Analysis of Gene Engineered Subunit Vaccine
Figure 68. Gene Engineered Subunit Vaccine Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
Figure 1. Gene Engineered Subunit Vaccine Picture
Figure 2. Global Gene Engineered Subunit Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Therapeutic Gene Engineered Subunit Vaccine
Figure 5. Preventative Gene Engineered Subunit Vaccine
Figure 6. Global Gene Engineered Subunit Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Gene Engineered Subunit Vaccine Consumption Value Market Share by Application in 2022
Figure 8. Human Use Picture
Figure 9. Veterinary Use Picture
Figure 10. Global Gene Engineered Subunit Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Gene Engineered Subunit Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Gene Engineered Subunit Vaccine Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Gene Engineered Subunit Vaccine Consumption Value Market Share by Region in 2022
Figure 15. North America Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Gene Engineered Subunit Vaccine Revenue Share by Players in 2022
Figure 21. Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Gene Engineered Subunit Vaccine Market Share in 2022
Figure 23. Global Top 6 Players Gene Engineered Subunit Vaccine Market Share in 2022
Figure 24. Global Gene Engineered Subunit Vaccine Consumption Value Share by Type (2018-2023)
Figure 25. Global Gene Engineered Subunit Vaccine Market Share Forecast by Type (2024-2029)
Figure 26. Global Gene Engineered Subunit Vaccine Consumption Value Share by Application (2018-2023)
Figure 27. Global Gene Engineered Subunit Vaccine Market Share Forecast by Application (2024-2029)
Figure 28. North America Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 38. France Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Gene Engineered Subunit Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 45. China Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 48. India Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Gene Engineered Subunit Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Gene Engineered Subunit Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 62. Gene Engineered Subunit Vaccine Market Drivers
Figure 63. Gene Engineered Subunit Vaccine Market Restraints
Figure 64. Gene Engineered Subunit Vaccine Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Gene Engineered Subunit Vaccine in 2022
Figure 67. Manufacturing Process Analysis of Gene Engineered Subunit Vaccine
Figure 68. Gene Engineered Subunit Vaccine Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
